Alnylam Pharmaceuticals will implement a strategic corporate restructuring, eliminating approximately 33% of its workforce to focus resources on its Alnylam 5×15 RNAi therapeutic product strategy and ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR) and ALN-APC for the treatment of hemophilia, as well as other pipeline programs with existing alliances and new partnerships. Alnylam expects to save approximately $20 million in 2012 and will incur one-time restructuring co...